Drugs Information Online
Drugs and diseases reference index

Drugs and diseases reference index

Drugs A-Z List

Diseases & Conditions A-Z List

Herbs & Supplements

Medical Dictionary

Full Article

Popular Drugs

Popular Diseases & Conditions

Drugs reference index «Rabeprazole Sodium»

Rabeprazole Sodium

Rabeprazole Sodium

Pronunciation: (ra-BEP-ra-zole SOE-dee-um)Class: Proton pump inhibitor

Trade Names:Aciphex- Tablets, delayed-release 20 mg

Pariet (Canada)


Suppresses gastric acid secretion by blocking acid (proton) pump within gastric parietal cells.



T max is 2 to 5 h. Oral bioavailability is about 52%.


Protein binding is 96.3%.


Extensively metabolized in liver by CYP3A to sulfone metabolite and CYP2C19 to desmethyl rabeprazole. Thioether metabolite is formed by reduction of rabeprazole. These metabolites do not have significant antisecretory activity. CYP2C19 exhibits genetic polymorphism caused by deficiency in some subpopulations (white patients, 3% to 5%; Asian patients, 17% to 20%).


Plasma t ½ is 1 to 2 h. Eliminated in urine (90% as thioether carboxylic acid, glucuronide, and mercapturic acid); remainder recovered in feces. No unchanged drug recovered.

Special Populations

Renal Function Impairment

No pharmacokinetic differences were observed in 10 patients with end-stage renal disease compared with 10 healthy volunteers.

Hepatic Function Impairment

For chronic mild to moderate hepatic function impairment, AUC approximately doubled and elimination t ½ was 2 to 3 fold higher, total Cl decreased to less than half. For mild to moderate hepatic function impairment, C max increased about 20% (not significant).


AUC values doubled, C max increased 60%.


Pharmacokinetics in patients 12 to 16 yr of age with GERD were within range observed in healthy adults.


Pharmacokinetics did not differ between men and women.


Values for AUC for healthy Japanese men were approximately 50% to 60% higher than values for healthy men in the United States.

Indications and Usage

Short-term treatment in healing and symptomatic relief of duodenal ulcers and erosive or ulcerative gastroesophageal reflux disease (GERD); maintaining healing and reducing relapse rates of heartburn symptoms in adults and children 12 yr of age and older with GERD; treatment of daytime and nighttime heartburn and other symptoms associated with GERD; long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome; in combination with amoxicillin and clarithromycin to eradicate Helicobacter pylori .


Known hypersensitivity to rabeprazole or substituted benzimidazoles.

Dosage and Administration

Healing of Duodenal UlcersAdults

PO 20 mg/day after the morning meal for 4 wk; additional therapy may be required for some patients.

Short-Term Treatment of GERDAdults and Children 12 yr of age and older

PO 20 mg once daily for up to 8 wk.

Treatment of Erosive or Ulcerative GERDAdults

PO 20 mg/day for 4 to 8 wk; an additional 8 wk may be considered for patients who do not heal.

Maintenance of Erosive or Ulcerative GERDAdults

PO 20 mg/day.

Treatment of Pathological Hypersecretory ConditionsAdults

PO 60 mg/day. Doses up to 100 mg daily or 60 mg twice daily have been administered.

H. Pylori Eradication to Reduce Risk of Duodenal Ulcer RecurrenceAdults

PO rabeprazole 20 mg plus amoxicillin 1,000 mg plus clarithromycin 500 mg twice daily for 7 days with morning and evening meals.

General Advice

  • Swallow tablets whole; do not chew, crush, or split.
  • May take with or with out food.


Store tablets at controlled room temperature (59° to 86°F). Protect from moisture.

Drug Interactions


Atazanavir plasma concentrations may be reduced, decreasing the efficacy. Coadministration is not recommended.

Drugs dependent on gastric pH for absorption (eg, digoxin, ketoconazole)

Plasma levels of digoxin may be increased, while ketoconazole concentrations may be decreased.


Increased INR and PT have been reported with concurrent rabeprazole.

Laboratory Test Interactions

None well documented.

Adverse Reactions


Headache (10%); dizziness; disorientation/delirium (postmarketing).


Bullous eruptions, severe dermatologic eruptions including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (postmarketing).


Pharyngitis (3%).


Diarrhea, nausea (5%); abdominal pain, vomiting (4%); flatulence (3%); constipation (2%); abdominal pain; dry mouth.


Interstitial nephritis (postmarketing).


Hepatic encephalopathy; hepatitis; increased hepatic enzymes; jaundice (postmarketing).


Agranulocytosis, hemolytic anemia, leukopenia, pancytopenia, thrombocytopenia (postmarketing).


Hyperammonemia, TSH elevations (postmarketing).


Arthralgia; myalgia; rhabdomyolysis (postmarketing).


Interstitial pneumonia (postmarketing).


Pain (3%); infection (2%); peripheral edema; anaphylaxis, angioedema, coma, sudden death (postmarketing).



Category B .




Safety and efficacy not established in the short-term treatment of GERD in children younger than 12 yr of age. For other indications, safety and efficacy not established.

Hepatic Function

Use with caution in patients with severe hepatic function impairment.

Gastric malignancy

Symptomatic response to rabeprazole does not preclude gastric malignancy.



No experience with large doses.

Patient Information

  • Instruct patient to take each dose without regard to meals but to take with food if stomach upset occurs.
  • Instruct patient to swallow tablets whole and not to split, crush, or chew the tablets.
  • Remind patient that rabeprazole is to be taken every day and not as needed or only when symptoms are present.
  • Remind patient that antacids may be taken concurrently with rabeprazole.
  • Instruct patient to report any of the following to health care provider: bloody or coffee ground vomit; black, tarry stools; recurrent heartburn; recurrent indigestion or abdominal pain; increasing need for antacid use; or bothersome adverse reactions (eg, headache, constipation, gas).

Copyright © 2009 Wolters Kluwer Health.

Comment «Rabeprazole Sodium»